New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort

American Journal of Gastroenterology

Volumn 103, Issue 3, 2008, Pages 665-681

  Papp, Maria ^a   Altorjay, Istvan ^a   Dotan, Nir ^b   Palatka, Karoly ^a   Foldi, Ildiko ^a   Tumpek, Judit ^a   Sipka, Sandor ^a   Udvardy, Miklos ^a   Dinya, Tamas ^a   Lakatos, Laszlo ^c   Kovacs, Agota ^d   Molnar, Tamas ^e   Tulassay, Zsolt ^f   Miheller, Pal ^f   Norman, Gary L ^g   Szamosi, Tamas ^f,h   Papp, Janos ^f   Lakatos, Peter L ^f  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Glycominds Ltd   (Israel)

^c Csolnoky F County Hospital   (Hungary)

^d Gastroenterological Department   (Hungary)

^e UNIVERSITY OF SZEGED   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g INOVA DIAGNOSTICS INC   (United States)

^h NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CARBOHYDRATE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHITOBIOSIDE; LAMINARIBIOSIDE; MANNOBIOSIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; ENTERITIS; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUNGARY; IMMUNOASSAY; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SACCHAROMYCES CEREVISIAE; SEROLOGY; SERUM; ULCERATIVE COLITIS;

ADULT; AGE OF ONSET; ANTIBODIES; BACTERIAL OUTER MEMBRANE PROTEINS; BIOLOGICAL MARKERS; CHITIN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; HUNGARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; POLYSACCHARIDES; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY;

EID: 40949094473     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01652.x     Document Type: Article

References (31)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 29.
2. Lakatos PL, Fischer S, Lakatos L, et al. Current concept on the pathogenesis of IBD: Crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"? World J Gastroenterol 2006 12 : 1829 40.
3. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease (IBD) in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study. World J Gastroenterol 2003 9 : 2300 7.
4. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World J Gastroenterol 2007 13 : 2028 36.
5. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 2006 12 : 6102 8.
6. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1998 42 : 788 91.
7. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serology testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001 96 : 758 65.
8. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988 297 : 1105 6.
9. Vermeire S, Jossens S, Peeters M, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in infammatory bowel disease. Gastroenterology 2001 120 : 827 33.
10. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001 96 : 730 4.
11. Papp M, Altorjay I, Norman GL, et al. Sero-reactivity to microbial components in Crohn's disease is associated with ileal involvement, non-inflammatory disease behaviour and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 2007 13 : 984 92.
12. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004 99 : 2376 84.
13. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004 53 : 1117 22.
14. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: Diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004 99 : 2235 41.
15. Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 139 46.
16. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006 101 : 645 52.
17. Henckaerts LC, Pierik M, Jossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007 56 : 1536 42.
18. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004 126 : 414 24.
19. Dotan I, Fishman S, Dgani Y et al. Antibodies against laminaribioside and chitobioside are novel serological markers in Crohn's disease. Gastroenterology 2006 131 : 366 78.
20. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007 56 : 1394 403.
21. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989 24 (Suppl 170 2 6.
22. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut 2006 55 (Suppl I I1 15.
23. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000 6 : 8 15.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl A 5 36.
25. Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in eastern Europe. Postgrad Med J 2006 82 : 270 3.
26. Terjung B, Worman HJ, Herzog V, et al. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 2001 126 : 37 46.
27. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005 54 : 1232 6.
28. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression. Am J Gastroenterol 2006 101 : 360 7.
29. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004 10 : 521 8.
30. Dassapoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: Higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007 13 : 143 51.
31. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: A stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003 98 : 2226 31.